

BIODOL Therapeutics Enters into License Agreement with KYORIN Pharmaceutical for Novel Neuropathic Pain Treatment

Montarnaud, France, 31 March 2026, 9AM CET Time – BIODOL Therapeutics (“BIODOL”), announced today that KYORIN Pharmaceutical Co., Ltd. (“KYORIN”) has exercised its option under the option agreement signed in January 2025 with BIODOL and entered into a license agreement for BDT272, a novel pain treatment candidate discovered by BIODOL.

Under the terms of this agreement, KYORIN has obtained exclusive rights to develop, manufacture, and commercialize BDT272 in Japan, South Korea, and Taiwan. In consideration for these rights, KYORIN will make payment to BIODOL up to 79 million euros based on upfront payment, milestone payments related to the progress of development, regulatory approval and the achievement of certain net sales targets. In addition, KYORIN will pay royalties to BIODOL based on net sales.

BDT272, completing Ph1 studies, is anticipated to demonstrate effective analgesic properties through the inhibition of FLT3, a receptor tyrosine kinase implicated in the pathogenesis and maintenance of pain condition such as neuropathic pain.

KYORIN aims to create high-value new drugs that meet medical needs and focuses on pain as one of our key strategic therapeutic area for research and development. KYORIN anticipates that this innovative pain treatment candidate will provide a new treatment option for patients suffering from pain conditions.

"This agreement further validates BIODOL's business model, which is to advance BDT272 through early- and mid-stage development and subsequently partner with established pharmaceutical companies, such as KYORIN, that have proven capabilities in clinical development and commercial deployment. This year of close collaboration with KYORIN's teams has strengthened our confidence in the quality of this partnership." said Fabien GRANIER, CEO of BIODOL Therapeutics.

"Our partnership with BIODOL represents a powerful synergy that elevates our drug discovery pipeline to new heights. We are fully dedicated to advancing our clinical program in Japan, driven by a shared vision to redefined pain treatment and bring hope to those in need. This is a bold step forward in KYORIN's evolution." said Yutaka OGIHARA, President and CEO of KYORIN Pharmaceutical Co., Ltd.

About KYORIN Pharmaceutical

KYORIN Pharmaceutical Co., Ltd. (www.kyorin-pharm.co.jp/en/) was founded in 1923. KYORIN operates under the corporate philosophy, "KYORIN continues to fulfil its mission of cherishing life and benefiting society by contributing to better health." Based on this principle, KYORIN aims to continuously provide high-value new drugs that meet medical needs, striving to become a company that contributes broadly to people's health. In drug discovery, KYORIN focuses its research efforts on the therapeutic areas of pain and autoimmune disorders and neuromuscular disease, working to create innovative new drugs that meet significant medical needs. In sales, KYORIN implements a Franchise Customer (FC) strategy, concentrating our resources on specialized areas, respiratory, otolaryngology, and urology.

About BIODOL Therapeutics

BIODOL Therapeutics (www.biodol.eu), founded in 2015, specializes in developing first-in-class compounds for pain treatment. The company has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key driver in initiating and sustaining neuropathic pain (Nature Communications, 2018). Its groundbreaking research has also demonstrated that inhibiting FLT3 signaling eliminates opioid tolerance and hyperalgesia while preserving analgesic efficacy (Nature Communications, 2024). BIODOL Therapeutics is focused on developing allosteric inhibitors of the FLT3 receptor to address various types of pain. The company holds exclusive rights to a portfolio of four patents and has received support from BPI France, SATT AxLR, Inserm Transfert, Région Occitanie, the French National Research Agency, SEMIA Incubator, and the Montpellier Business and Innovation Centre. BIODOL Therapeutics was assisted by MCE Carrel law firm for this transaction.

For more information, please contact:

Biodol Therapeutics

contact@biodol.eu